Study Information

CLBS119 is a Phase 1, open-label, proof-of-concept clinical trial that will explore the safety and potential efficacy of peripheral blood derived autologous CD34+ cells (CLBS119) for the repair of COVID-19-induced lung damage in adults. The study will target patients who are experiencing hypoxia due to prior infection with SARS-CoV-2 and who require supplemental oxygen. For more information on this study, please visit

Status: Active - Enrolling